调整心率和去甲肾上腺素剂量后舒张压能更好反映脓毒性休克严重程度
本研究为ANDROMEDA-SHOCK数据库的事后分析,纳入424例接受去甲肾上腺素治疗的脓毒性休克患者,在随机化时点(诊断后4小时内)记录血流动力学变量和初始去甲肾上腺素剂量。采用多变量模型比较VNERi=舒张压/(去甲肾上腺素剂量×心率)与舒张压、舒张压/心率、平均动脉压/去甲肾上腺素剂量同院内死亡率、28天内无血管活性药物天数和无肾脏替代治疗天数的关联。结果显示VNERi与院内死亡率的关联最强,是多变量模型中最显著的协变量,且院内死亡率与VNERi呈倒J形关系,最低点在6.7,低于此值死亡率增加。作者认为VNERi可能作为床旁血管对去甲肾上腺素反应性的标志物,并可能整合到早期脓毒性休克的决策中。
要点
- 在424例接受去甲肾上腺素治疗的脓毒性休克患者中,VNERi=舒张压/(去甲肾上腺素剂量×心率)与院内死亡率的关联强于舒张压、舒张压/心率及平均动脉压/去甲肾上腺素剂量。
- VNERi与院内死亡率呈倒J形关系,最低点在6.7,低于此值死亡率增加。
- VNERi与28天内无血管活性药物天数和无肾脏替代治疗天数的关联也强于其他指标。
- 纳入时中位舒张压为52 mmHg(IQR 45-50),中位去甲肾上腺素剂量为0.2 µg/kg/min(IQR 01-0.4),院内死亡率为43%。
- 作者认为VNERi可能作为床旁血管对去甲肾上腺素反应性的标志物,并可能整合到早期脓毒性休克的决策中。
适用人群与场景
- ANDROMEDA-SHOCK数据库中的脓毒性休克患者,随机化时点(诊断后4小时内)接受去甲肾上腺素治疗。
研究设计与关键结果
- 研究类型:ANDROMEDA-SHOCK数据库的事后分析,纳入424例接受去甲肾上腺素治疗的脓毒性休克患者。
- 在随机化时点(诊断后4小时内)记录血流动力学变量和初始去甲肾上腺素剂量,去甲肾上腺素剂量以µg/kg/min表示(使用酒石酸去甲肾上腺素制剂)。
- 中位舒张压为52 mmHg(IQR 45-50),中位去甲肾上腺素剂量为0.2 µg/kg/min(IQR 01-0.4),院内死亡率为43%。
- VNERi与院内死亡率的关联强于舒张压、舒张压/心率及平均动脉压/去甲肾上腺素剂量,是多变量模型中最显著的协变量。
- VNERi与28天内无血管活性药物天数和无肾脏替代治疗天数的关联也强于其他指标。
- 院内死亡率与VNERi呈倒J形关系,最低点在6.7,低于此值死亡率增加。
证据类型、等级与局限
- 证据类型:基于ANDROMEDA-SHOCK数据库的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,VNERi可能作为床旁血管对去甲肾上腺素反应性的标志物,并可能整合到早期脓毒性休克的决策中。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Septic shock is commonly associated with reduction in vasomotor tone, mainly due to vascular hyporesponsiveness to norepinephrine (NE). Although the diastolic arterial pressure (DAP)/heart rate (HR) ratio reflects vasomotor tone, it cannot be a reliable index of vascular responsiveness to NE (VNERi). We hypothesized that adjusting DAP/HR for the NE dose could yield a VNERi value (VNERi = DAP/(NE dose x HR)), knowledge of which can help guiding therapeutic strategies in cases of persistent hypotension despite NE (e.g., increasing NE doses vs. introducing additional vasopressors). For our hypothesis be valid, at least VNERi should demonstrate a stronger association with patient outcome than DAP, DAP/HR or mean arterial pressure (MAP)/NE dose, a global marker of NE responsiveness.
METHODS: We conducted a post-hoc analysis of the ANDROMEDA-SHOCK database. Hemodynamic variables and initial NE doses were recorded at the randomization time-point, within 4 h of septic shock diagnosis. NE doses were expressed in µg/kg/min (using the bitartrate NE formulation). A multivariate model was employed to compare the associations between these variables and key clinical outcomes, including in-hospital mortality, numbers of vasopressor-free days and of renal replacement therapy (RRT)-free days up to day 28.
RESULTS: The ANDROMEDA-SHOCK database included 424 patients with septic shock receiving NE. The median DAP was 52 mmHg [IQR: 45-50] and the median NE dose at inclusion was 0.2 µg/kg/min [IQR: 01-0.4]. In-hospital mortality was 43%. VNERi demonstrated the strongest association with in-hospital mortality compared to DAP, DAP/HR, and MAP/NE dose, emerging as the most significant covariate in the multivariate model. Similar findings were found for the associations with numbers of vasopressor-free days and RRT-free days up to day 28. The model revealed an inverted J-shaped relationship between in-hospital mortality and VNERi, with a nadir point at 6.7, below which mortality increased.
CONCLUSIONS: In patients receiving NE during early septic shock, VNERi demonstrated the strongest association with outcome compared to DAP, DAP/HR, and MAP/NE dose. Due to its physiological basis and robust association with outcomes, VNERi may serve as a valuable bedside marker of the vascular responsiveness to NE. This index could potentially be integrated into decision-making of early septic shock.
参考来源
- Goury A, Djerada Z, Hernandez G, et al. Ability of diastolic arterial pressure to better characterize the severity of septic shock when adjusted for heart rate and norepinephrine dose. Ann Intensive Care. 2025. PMID: 40133652. doi:10.1186/s13613-025-01454-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。